A 72-year-old woman was admitted to the ICU 8 days ago with acute respiratory distress syndrome secondary to sepsis. She has been on mechanical ventilation with a cuffed endotracheal tube. Today she develops a new fever (39.2°C), purulent endotracheal secretions, and a new infiltrate on chest X-ray in the right lower lobe. Blood cultures are negative. Sputum culture is pending. What is the most likely diagnosis, and which organism should empirical therapy cover as a priority?

Explanation

## Diagnostic Criteria for VAP **Key Point:** Ventilator-Associated Pneumonia (VAP) is defined as pneumonia occurring **≥48 hours after intubation** in a mechanically ventilated patient. This patient meets VAP criteria: - 8 days of mechanical ventilation (well beyond 48-hour threshold) - New fever - Purulent endotracheal secretions - New infiltrate on imaging - Negative blood cultures (typical in VAP) ## Microbiology of VAP **High-Yield:** VAP microbiology differs significantly from CAP due to **aspiration of oropharyngeal flora** colonized with gram-negative organisms and *Staphylococcus aureus*. | Organism | Frequency in VAP | Risk Factors | |---|---|---| | *Pseudomonas aeruginosa* | 30–40% | Most common gram-negative; high mortality | | *Acinetobacter baumannii* | 15–25% | ICU-endemic, often MDR | | *Staphylococcus aureus* (MRSA) | 15–20% | ICU-endemic, high mortality | | *Enterobacteriaceae* (*E. coli*, *Klebsiella*) | 20–30% | Common but lower mortality | | *Streptococcus pneumoniae* | <5% | Rare in VAP; more common in CAP | **Clinical Pearl:** *Pseudomonas aeruginosa* and *Acinetobacter baumannii* are the **most feared organisms in VAP** due to high mortality (25–40%) and frequent multidrug resistance. These gram-negative rods thrive in the ICU environment and are acquired through aspiration of contaminated secretions. ## Why NOT the Other Options? **Mnemonic — VAP vs. CAP Pathogens (GRAM-NEGATIVE):** - VAP: **G**ram-negatives (*Pseudomonas*, *Acinetobacter*, *Enterobacteriaceae*), **R**esistant *Staph* (MRSA) - CAP: **S**treptococcus *pneumoniae*, **H**aemophilus *influenzae*, **M**ycoplasma, **L**egionella **Option 0** (CAP pathogens): *S. pneumoniae* and *H. influenzae* are characteristic of CAP, not VAP. These organisms are rare in VAP (<5%). **Option 2** (HAP low-risk): Even though this patient is technically in the hospital, she meets VAP criteria (intubated ≥48 hours). HAP low-risk pathogens are inappropriate; this patient requires broad gram-negative coverage. **Option 3** (CAP superimposed): *Legionella* and *Mycoplasma* are atypical CAP pathogens. They do not cause VAP. The clinical presentation (ICU, mechanical ventilation, purulent secretions) is classic VAP, not CAP. ## Empirical Therapy for VAP For this patient with **late-onset VAP (≥5 days)**, empirical therapy should include: - **Antipseudomonal β-lactam** (piperacillin-tazobactam, cefepime, or meropenem) AND - **Antipseudomonal fluoroquinolone** (ciprofloxacin or levofloxacin) OR - **Aminoglycoside** (tobramycin or amikacin) AND - **Anti-MRSA agent** (vancomycin or linezolid) if risk factors for MRSA present [cite:Harrison 21e Ch 297; IDSA VAP Guidelines 2016]